Drug Profile
PF 06423264
Alternative Names: PF-06423264Latest Information Update: 10 May 2018
Price :
$50
*
At a glance
- Originator Pfizer
- Class Skin disorder therapies
- Mechanism of Action Acetyl-CoA carboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 01 May 2018 Discontinued - Phase-I for Acne in Belgium (Topical) (Pfizer pipeline, May 2018)
- 23 May 2017 Pfizer terminates a phase I trial for Acne in Healthy volunteers in Belgium (Topical) (NCT02778477)
- 23 May 2016 Phase-I clinical trials in Acne (In volunteers) in Belgium (Topical)